U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830888) titled 'Mitral Valve Prolapse Arrhythmic Risk' on Sept. 15.
Brief Summary: Mitral valve prolapse (MVP) is common with a 2-3 % prevalence in the general association and generally associated with a favorable prognosis. However, a subgroup of MVP patients, known as arrhythmic mitral valve prolapse (AMVP) has an increased burden of severe ventricular arrhythmias and risk of sudden cardiac death. Identifying high risk patients who may benefit of potential implantable cardioverter-defibrillator (ICD) implantation is therefore critically important. Risk stratification in AMVP is still challenging, and the ability to estimate arrhythmic risk at th...